Medindia

X

Tarceva Helps Prolong Disease-Free Progression in Lung Cancer Patients

by Kathy Jones on  June 4, 2011 at 5:39 PM Drug News   - G J E 4
A group of British researchers has found that a tablet that is currently being sold by the NHS is more effective than standard chemotherapy and can double the survival chances for patients suffering from lung cancer.
 Tarceva Helps Prolong Disease-Free Progression in Lung Cancer Patients
Tarceva Helps Prolong Disease-Free Progression in Lung Cancer Patients
Advertisement

The drug, known as erlotinib, is sold by the NHS under the brand name Tarceva. The researchers found that those who took a daily dose of Tarceva managed to go 9.7 months without disease progression compared to just 5.2 months among lung cancer patients who were given standard chemotherapy.

Advertisement
In a study involving more than 1,200 patients, the researchers found that erlotinib reduced the risk of the cancer spreading by more than 63 percent and had none of the severe side effects experienced by chemotherapy patients.

Commenting on the study, the consultant medical oncologist at Aberdeen Royal Infirmary, Dr Marianne Nicolson told the Daily Mirror, "These results are very exciting. Tarceva is already used after ¬chemotherapy, and this study demonstrates what can be achieved when it is used as an initial treatment."


Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All